Department of Plastic and Reconstructive Surgery, Ninth People's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200011, China.
Department of Burns, Second Affiliated Hospital of Shandong First Medical University, Taian, China.
Anal Cell Pathol (Amst). 2021 Feb 10;2021:8883427. doi: 10.1155/2021/8883427. eCollection 2021.
Keloids are scars characterized by abnormal proliferation of fibroblasts and overproduction of extracellular matrix components including collagen. We previously showed that LY2109761, a transforming growth factor- (TGF-) receptor inhibitor, suppressed the secretion of matrix components and slowed the proliferation of fibroblasts derived from human hypertrophic scar tissue. However, the exact mechanism underlying this effect remains unclear. Here, we replicated the above results in keloid-derived fibroblasts and show that LY2109761 promoted apoptosis, decreased the phosphorylation of Smad2 and Smad3, and suppressed TGF-1. These results suggest that the development and pathogenesis of keloids are positively regulated by the Smad2/3 signaling pathway and the upregulation of TGF-1 receptors. LY2109761 and other inhibitors of these processes may therefore serve as therapeutic targets to limit excessive scarring after injury.
瘢痕疙瘩是一种以成纤维细胞异常增殖和细胞外基质成分(包括胶原)过度产生为特征的瘢痕。我们之前的研究表明,LY2109761,一种转化生长因子-β(TGF-β)受体抑制剂,可抑制基质成分的分泌并减缓人增生性瘢痕组织来源的成纤维细胞的增殖。然而,其确切的作用机制尚不清楚。在此,我们在瘢痕疙瘩衍生的成纤维细胞中复制了上述结果,并表明 LY2109761 可促进细胞凋亡、降低 Smad2 和 Smad3 的磷酸化,并抑制 TGF-β1。这些结果表明,Smad2/3 信号通路和 TGF-β1 受体的上调正向调节了瘢痕疙瘩的发生和发病机制。因此,LY2109761 和其他这些过程的抑制剂可能成为限制损伤后过度瘢痕形成的治疗靶点。